ONCOMATRYX BIOPHARMA

Developing a diversified portfolio of precision ADCs (+Ph1 data) and small molecules (+Ph1b-2a data) targeting the tumor microenvironment (stroma) of highly invasive solid tumors, as well as other high-value unmet cancer, fibrotic & CNS indications